ArticleFrontiers in medicine2026
Solitary adrenal metastatic adenocarcinoma one year after radical gastrectomy for gastric cancer: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adrenal metastasis from gastric cancer is rare and usually occurs as part of widespread systemic dissemination. Solitary adrenal metastasis detected during postoperative follow-up is extremely uncommon and easily overlooked due to nonspecific clinical manifestations. Case presentation: We report the case of a 69-year-old man who underwent radical gastrectomy for esophagogastric junction cancer one year earlier. Histopathology revealed diffuse infiltrative mucinous adenocarcinoma with components of signet-ring cell carcinoma and neuroendocrine carcinoma (pT4N3Mx). The patient completed six cycles of adjuvant chemotherapy with tegafur-gimeracil-oteracil (S-1) plus oxaliplatin, and routine follow-up examinations showed no evidence of recurrence. Twenty-one months postoperatively, he presented with left upper abdominal pain. Computed tomography revealed a solitary mass in the left adrenal gland. Tumor markers, including CA72-4, CA19-9, and carcinoembryonic antigen, were markedly elevated. Ultrasound-guided biopsy confirmed metastatic adenocarcinoma of gastric origin. The patient was treated with SOX chemotherapy combined with the PD-1 inhibitor tislelizumab. After the first treatment cycle, his general condition improved, and he remains under close follow-up. Conclusion: This case highlights the importance of vigilance for rare metastatic sites, such as the adrenal gland, in patients with advanced gastric cancer even after standardized postoperative surveillance. Systemic chemotherapy combined with immunotherapy may represent an effective treatment strategy for selected patients with metastatic gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.